移动卒中单元:证据、空白与下一步
移动卒中单元(MSU)是配备人员、设备和影像能力以在院前诊治急性卒中的特种救护车。过去十年MSU在全球尤其欧洲和美国城市增多并成立国际联盟。随机试验显示MSU提高溶栓率并缩短发病至治疗时间;2021年B_PROUD和BEST-MSU两项大型对照临床试验表明,与常规急诊护理相比,MSU治疗安全并改善卒中患者功能结局,获益主要来自黄金一小时内超早期溶栓频率更高。但成本效益、非城市环境效用和最佳基础设施仍存疑问,且全球多地MSU尚未被保险报销或监管机构接受为标准 care。
要点
- 随机试验显示MSU提高卒中溶栓率并缩短发病至治疗时间。
- 2021年B_PROUD和BEST-MSU试验表明MSU治疗安全并改善功能结局。
- MSU获益主要来自黄金一小时内超早期溶栓频率更高。
核心结论
- 与常规急诊护理相比,MSU治疗安全并改善卒中患者功能结局,获益主要来自黄金一小时内超早期溶栓频率更高。
- MSU已成为少数经证实有效的急性卒中干预之一,效应量与静脉溶栓和卒中单元相当。
- MSU的成本效益、在非城市环境的效用和最佳基础设施仍存疑问。
- 全球多地MSU目前未被保险报销,也未被监管机构接受为标准 care。
研究设计与样本
- 综述性文章,总结MSU的证据、空白与下一步,提及B_PROUD和BEST-MSU两项大型对照临床试验。
主要发现
- 随机试验已证明MSU提高卒中溶栓率并缩短发病至治疗时间。
- 2021年B_PROUD和BEST-MSU试验表明,与常规急诊护理相比,MSU治疗安全并改善卒中患者功能结局。
- MSU的观察获益主要来自黄金一小时内超早期溶栓频率更高。
临床怎么用
- 卒中领导者和组织应与急救医疗服务、政府和社区利益相关者合作,确定MSU如何使各个社区受益及其最佳组织和融资方式。
- 推荐的下一步包括保险报销、与救护车网络整合、获得项目认证机构认可和纳入监测护理质量的登记系统。
局限性
- MSU的成本效益仍存疑问。
- MSU在非城市环境的效用仍存疑问。
- MSU的最佳基础设施仍存疑问。
- 全球多地MSU目前未被保险报销,也未被监管机构接受为标准 care。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mobile stroke units (MSUs) are specialized ambulances equipped with the personnel, equipment, and imaging capability to diagnose and treat acute stroke in the prehospital setting. Over the past decade, MSUs have proliferated throughout the world, particularly in European and US cities, culminating in the formation of an international consortium. Randomized trials have demonstrated that MSUs increase stroke thrombolysis rates and reduce onset-to-treatment times but until recently it was uncertain if these advantages would translate into better patient outcomes. In 2021, 2 pivotal, large, controlled clinical trials, B_PROUD and BEST-MSU, demonstrated that as compared with conventional emergency care, treatment aboard MSUs was safe and led to improved functional outcomes in patients with stroke. Further, the observed benefit of MSUs appeared to be primarily driven by the higher frequency of ultra-early thrombolysis within the golden hour. Nevertheless, questions remain regarding the cost-effectiveness of MSUs, their utility in nonurban settings, and optimal infrastructure. In addition, in much of the world, MSUs are currently not reimbursed by insurers nor accepted as standard care by regulatory bodies. As MSUs are now established as one of the few proven acute stroke interventions with an effect size that is comparable to that of intravenous thrombolysis and stroke units, stroke leaders and organizations should work with emergency medical services, governments, and community stakeholders to determine how MSUs might benefit individual communities, and their optimal organization and financing. Future research to explore the effect of MSUs on intracranial hemorrhage and thrombectomy outcomes, cost-effectiveness, and novel models including the use of rendezvous transports, helicopters, and advanced neuroimaging is ongoing. Recommended next steps for MSUs include reimbursement by insurers, integration with ambulance networks, recognition by program accreditors, and inclusion in registries that monitor care quality.
引用
- Navi BB, Audebert HJ, Alexandrov AW, et al. Mobile Stroke Units: Evidence, Gaps, and Next Steps. Stroke. 2022. PMID: 35331008. doi:10.1161/STROKEAHA.121.037376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。